These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8754440)

  • 1. Hydroxyurea in sickle cell disease.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(4):210. PubMed ID: 8754440
    [No Abstract]   [Full Text] [Related]  

  • 2. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
    Brandow AM; Panepinto JA
    Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.
    Olnes M; Chi A; Haney C; May R; Minniti C; Taylor J; Kato GJ
    Am J Hematol; 2009 Aug; 84(8):530-32. PubMed ID: 19536844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
    Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
    Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
    [No Abstract]   [Full Text] [Related]  

  • 7. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 8. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
    Nnebe-Agumadu U; Adebayo IA; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28632. PubMed ID: 32743869
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
    Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA; Al-Khawlani MM; Al-Akwa A
    Hemoglobin; 2011; 35(1):13-21. PubMed ID: 21250877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
    Fitzhugh CD; Wigfall DR; Ware RE
    Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
    Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
    PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 15. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.
    Grace RF; Su H; Sena L; Poussaint TY; Heeney MM; Gutierrez A
    Am J Hematol; 2010 Feb; 85(2):135-7. PubMed ID: 20052745
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
    Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
    Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
    Wang WC
    Exp Biol Med (Maywood); 2016 Apr; 241(7):730-6. PubMed ID: 27026724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.